Total raised
$8.0M
Last: Series A 2024-11
Stage
Acquired
Founded
2020
Headcount
21
HQ
Rehovot
Sector
Health Tech & Life Sciences
About
MetaSight develops and deploys accurate, affordable, and accessible diagnostics for diverse diseases through a single blood test – applicable for population scale screening.
Its approach leverages the world’s largest clinico multi-OMICS database, generated using our proprietary unbiased metabolomics, lipidomics, and proteomics platform.
Funding history · 2 rounds · $8.0M total
2024-11
Series A
$8.0M
2022-04
Undisclosed
Undisclosed
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was MetaSight Diagnostics acquired and by whom?
- MetaSight Diagnostics was acquired by Guardant Health in February 2026.
- What was the acquisition amount for MetaSight Diagnostics?
- MetaSight Diagnostics was acquired for $150,000,000 in February 2026.
- What was the last funding round for MetaSight Diagnostics?
- MetaSight Diagnostics completed a Series A funding round in November 2024, raising $8,000,000.
- Which investors participated in MetaSight Diagnostics' Series A funding round?
- The Series A funding round for MetaSight Diagnostics in November 2024 included investors such as Saban Ventures, aMoon Fund, Alumni Ventures, and Arc Ventures.
- When was MetaSight Diagnostics founded?
- MetaSight Diagnostics was founded in April 2020.
- What is MetaSight Diagnostics' primary sector?
- MetaSight Diagnostics' primary sector is Health Tech & Life Sciences.
- How many employees does MetaSight Diagnostics have?
- MetaSight Diagnostics has between 11 and 50 employees.
- Who is a founder of MetaSight Diagnostics?
- Tomer Shlomi is a founder of MetaSight Diagnostics.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyTest Diagnostics & Screening
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business model
B2B
Tags
spectroscopyoncologydiagnosticspharmaceuticalsbiopsybiotechnologyinflammatory-diseasesblood-testbiomarkers